Herbalife Nutrition Ltd vs Vir Biotechnology Inc. Common Stock — how do they compare? Herbalife Nutrition Ltd trades at $13.76 (market cap $1.49B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: Vir Biotechnology Inc. Common Stock is the larger of the two by market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| HLF | VIR | |
|---|---|---|
Market Cap | $1.49B | $1.76B |
Volume | 1,695,348 | 2,764,948 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $11.78 |
52-Week Low | $7.75 | $5.12 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $3.32B | $1.32B |
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $14.21, up 4.41% today, with a bullish technical signal and strong analyst support. The stock shows attractive valuation metrics with a P/E of 9.11 and P/S of 0.29, while recent earnings have been mixed with a beat in Q1 2026 but a miss in Q2. The company maintains a high gross margin of 77.7% and has announced a $250 million share repurchase program, signaling confidence in its financial health.
The outlook for HLF is cautiously optimistic, supported by a consensus price target of $19.00 and a majority of analysts rating it a Buy. Key risks include inconsistent earnings performance, high debt levels, and ongoing leadership transition. Upside potential exists if the company can sustain revenue growth and improve net margins, but investors should monitor execution on debt reduction and quarterly results.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →